REVIEWS Moving from Basic Toward Systems Pharmacodynamic Models
暂无分享,去创建一个
[1] Matthew M Riggs,et al. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.
[2] J. Mandema,et al. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.
[3] A. J. Clark. The Rate of Action of Drugs on Cells , 1937 .
[4] Richard R. Almon,et al. Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.
[5] P. Toutain,et al. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. , 2000, The Journal of pharmacology and experimental therapeutics.
[6] W. Jusko,et al. Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys , 2004, Pharmaceutical Research.
[7] G. Ferron,et al. Pharmacodynamic Modeling of Pantoprazole's Irreversible Effect on Gastric Acid Secretion in Humans and Rats , 2001, Journal of clinical pharmacology.
[8] William J. Jusko,et al. Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[9] R R Almon,et al. Extracting Global System Dynamics of Corticosteroid Genomic Effects in Rat Liver , 2008, Journal of Pharmacology and Experimental Therapeutics.
[10] W J Jusko,et al. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.
[11] Gary An,et al. Translational Systems Biology of Inflammation , 2008, PLoS Comput. Biol..
[12] W J Jusko,et al. Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.
[13] T Iga,et al. Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. , 1996, Biological & pharmaceutical bulletin.
[14] Donald E. Mager,et al. Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems , 2010, The AAPS Journal.
[15] M Danhof,et al. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. , 1991, The Journal of pharmacology and experimental therapeutics.
[16] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[17] W. Jusko,et al. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. , 2005, British journal of clinical pharmacology.
[18] R. Ramakrishnan,et al. Fifth-Generation Model for Corticosteroid Pharmacodynamics: Application to Steady-State Receptor Down-Regulation and Enzyme Induction Patterns During Seven-Day Continuous Infusion of Methylprednisolone in Rats , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[19] R. Iyengar,et al. Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.
[20] Terrence P. Kenakin,et al. A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .
[21] Onn Brandman,et al. Feedback Loops Shape Cellular Signals in Space and Time , 2008, Science.
[22] R. Furchgott,et al. The pharmacology of vascular smooth muscle. , 1955, Pharmacological reviews.
[23] G. An. In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling* , 2004, Critical care medicine.
[24] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[25] DE Mager,et al. Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.
[26] W. Jusko,et al. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice , 2013, Cancer Chemotherapy and Pharmacology.
[27] W. Jusko,et al. Pharmacokinetic–Pharmacodynamic Modeling of Tolmetin Antinociceptive Effect in the Rat Using an Indirect Response Model: A Population Approach , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[28] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[29] W J Jusko,et al. Pharmacodynamic modeling of time‐dependent transduction systems , 2001, Clinical pharmacology and therapeutics.
[30] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .
[31] Joseph P. Balthasar,et al. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[32] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[33] Lawrence J Lesko,et al. Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.
[34] L. Lesko,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.
[35] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[36] John Anthony Bauer,et al. Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.
[37] Jianguo Zhi,et al. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[38] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[39] Richard R Almon,et al. Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.
[40] Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development , 1992 .
[41] J. Wagner,et al. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.
[42] C Garnett,et al. Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.
[43] G Levy,et al. Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.
[44] Hoi-Kei Lon,et al. Pharmacokinetic/pharmacodynamic modeling in inflammation. , 2012, Critical reviews in biomedical engineering.
[45] W J Jusko,et al. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.
[46] Yasuhiko Yamada,et al. Parmacodynamic Analysis of Antiplatelet Effect of Aspirin in the Literature. Modeling Based on Inhibition of Cyclooxygenase in the Platelet and the Vessel Wall Endothelium. , 1996 .
[47] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. , 2005, Basic & clinical pharmacology & toxicology.
[48] W J Jusko,et al. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.